Learning to Sleep publicerade den 24 augusti 2022 bolagets delårsrapport för det andra kvartalet 202...
Today (25 August), Cibus’ CEO Sverker Källgården and CFO Pia-Lena Olofsson presented at the Nordea S...
ChromoGenics publicerade den 25 augusti 2022 sin delårsrapport för årets andra kvartal.
Redeye comments on Cereno’s Q2 2022 report, and we judge that the company is making solid progress o...
Redeye leaves its comments on Idogen following the report for the second quarter of 2022.
E-tailers stack ut i kvartalet Björn Borg hade en omsättning om 162 mkr (163 mkr) i Q2, motsvarande ...
One of the important hurdles for the ramp-up of Zwipe Pay has been certification by Visa and Masterc...
Redeye comments on today’s Q2 report from Alzecure and reiterate our view of the company.
Affär med Corem slutförd Omsättningen i Q2'22 uppgick till 4,4 mdkr.
Fellow Bank started its banking operations in April and financial figures were accordingly burdened.
Redeye is encouraged to see Episurf delivering on its activities for inclusion in UK NICE guidelines...
Med första halvåret avklarat står det klart att Finepart fortsätter att uppvisa ett starkt momentum,...
Surprisingly strong order intake at E&P and MTH DK Order book increase to DKK 12bn bodes well for fu...
Redeye will only make smaller estimate changes as the quarterly financials were somewhat weaker than...
Redeye comments on C Security's Q2 report, which was below our expectations in terms of revenues but...
Redeye leaves a comment on the H1 report published by Faron Pharmaceuticals earlier today.
Q2: Limited deviations on sales and adj. EBITDA Small negative cons adj.
NOI of SEK 39m vs ABGSCe at SEK 42m Property value changes of SEK 33m – in line vs ABGSCe Net LTV of...
We adapt a NAV-focused approach Företagsparken the largest growth driver NAVPS growth 10% every year...
Vow published its H1 report this morning, with strong headline figures.
